Drugs / OC-IgT cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03184753 | May 2025 → Sep 2028 expected | ovarian cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OC-IgT cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03184753 ↗ |
| Modality | Cell therapy | “infusion of autologous ovarian cancer immunogene-modified T cells (OC-IgT cells)” NCT03184753 ↗ |
| Route | Intravenous | “by IV and intratumoral injection” NCT03184753 ↗ |
| Route | Other | “by IV and intratumoral injection” NCT03184753 ↗ |